SAN CARLOS, Calif., May  05, 2026  (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (&#34;Biomea&#34; or &#34;Biomea Fusion&#34; or &#34;the Company&#34;) (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that three

BMEA

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

Biomea Fusion to Present Promising Icovamenib Data at ADA 2026

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 SAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (&amp;#34;Biomea&amp;#34; or &amp;#34;Biomea Fusion&amp;#34; or &amp;#34;the Company&amp;#34;) (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that three
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 Biomea Fusion is set to showcase critical data on icovamenib at the upcoming ADA 2026 conference, focusing on its efficacy in improving beta cell function in diabetes. This key presentation on June 7 could significantly bolster investor confidence and impact Biomea&#039;s stock performance positively.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Biomea&#039;s icovamenib will be presented at the ADA 2026 conference.</li><li>Presentations include data on improving beta cell function for diabetes treatment.</li><li>Icovamenib may enhance insulin secretion and metabolic health.</li><li>Key findings will be revealed on June 7, 2026.</li><li>Presentations could boost confidence in Biomea&#039;s drug pipeline.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>Biomea Fusion, Inc. (BMEA): Anticipated data presentations may enhance investor sentiment regarding Biomea&#039;s pipeline.</li></ul>
 </section>

 <section data-block="category">
 <h3>Corporate Developments</h3>
 This news falls under &#039;Corporate Developments&#039; as it highlights a significant upcoming event for Biomea Fusion concerning its drug candidate&#039;s clinical data presentation. The resulting investor reactions to this data can influence stock performance significantly.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>Positive presentation outcomes could lead to a sharp stock price increase.</li><li>Market reaction may occur as data becomes public on June 5, 2026.</li><li>Investor sentiment could shift favorably leading into conference week.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>ADA 2026 takes place June 5-8, 2026, in New Orleans.</li><li>Three late-breaking abstracts on icovamenib will be presented.</li><li>Icovamenib is in Phase 2 clinical development for diabetes treatment.</li><li>The presentations are scheduled for June 7 at 12:30 PM CT.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Consider a bullish stance on BMEA leading up to the ADA presentation on June 7.
 </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link>SAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/BMEA">BMEA</a>), a clinical-stage diabetes and obesity company, today announced that three icovamenib abstracts have been selected for late-breaking poster presentations at the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5–8, 2026 in New Orleans. The presentations include data from icovamenib, the Company's investigational oral menin inhibitor, across both type 1 and type 2 diabetes, highlighting its potential to improve beta cell function and support metabolic health. Presentation Details Title: Glycemic Improvements with Icovamenib in T2D on Background GLP-1 Therapy: COVALENT-111 Subgroup Analysis Session: Late-Breaking Poster Session 2857-LB Presenter: Juan Pablo Frías, M.D. Date/Time: June 7, 2026, at 12:30 pm – 1:30 pm CT Title: Icovamenib, a Menin Inhibitor, Improves Endogenous Insulin Secretion in Type 1 Diabetes: Results from the COVALENT-112 Study Session: Late-Breaking Poster Session 2858-LB Presenter: Juan Pablo Frías, M.D. Date: June 7, 2026, at 12:30 pm – 1:30 pm CT Title: Menin Inhibitor Icovamenib Activates Mechanisms That Support Metabolic Health Session: Late-Breaking Poster Session 2871-LB Presenter: Mini Balakrishnan, Ph.D. Date/Time: June 7, 2026, at 12:30 pm – 1:30 pm CT All presentations will be available following the lifting of the embargo on Friday, June 5, 2026, at 6:30 PM CT. At that time, materials will be published on the Diabetes&#xAE; journal website and in the <a href="https://www.globenewswire.com/Tracker?data=nFO6fM_w3_ZIe1KLskoyn7CsExQFlCy1kQFbZMQeHQmFgsd-69L2EvVy54xD2yDttwPy_2aE3zTzkahz6-xHcp1zXvIldSB8NQ8U8FiNmEFaS1GztuAEgUGO15VDjI9VeIrD8k0woWjAyjYmYLqJbA==" rel="nofollow" target="_blank">Investors &amp; Media</a> section of Biomea's website. About Icovamenib Icovamenib is an orally administered investigational small molecule currently in Phase 2 clinical development for the treatment of diabetes. Icovamenib targets menin, a transcriptional regulator implicated in beta cell dysfunction, and has been shown in preclinical and clinical studies to induce transient reductions in menin protein levels in pancreatic islets, thereby modulating pathways associated with insulin secretion and glycemic control. Through this mechanism, icovamenib has the potential to restore beta cell mass and function and improve endogenous insulin production. As a potential short-course therapy, icovamenib could represent a novel treatment approach for patients with diabetes, particularly those who have not achieved adequate control with standard-of-care therapies. About Biomea Fusion Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world's population. Biomea's mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure. Visit us at <a href="https://www.globenewswire.com/Tracker?data=vC4pgxoevU1GsgMTiflI17jle9H26aK5XNr8Ugo-b94_VEhzTmsEba_3wuB20JrREImjI9djXMxzdiUtGhjniiBuKOWVtEcjFjmJbgK61dM=" rel="nofollow" target="_blank">www.biomeafusion.com</a> and follow us on <a href="https://www.globenewswire.com/Tracker?data=RQoWE-ndc0s-18CI3XfRQIsvCOptQ3GVzsRBVdL6ppxdDBL7VITAgFJnk-NscVx_ccxtXANAhMohTUNFmg5_ALGxJEJgEomJi1O67x745XgnMNTq6gAJNAOAWfbK0pjMLv_mhsRcbVAcnaFwBO2MAuhr93N_g2ELjkZAuSzyzUSbPwBYVYgaWGLiJ9MNQZ5F5eQ7lV9vbOySvmTP-dycxa4EcvmaPgBgRSbvRtBTHdop_An40bI0l2m8VlEMagYQilP38V3Fzx0BGUQsCBi73g==" rel="nofollow" target="_blank">LinkedIn</a>, <a href="https://www.globenewswire.com/Tracker?data=LR1ffQ01cMOP5XFwwq2yrVvd-hQ4KmRMGq6smDCCgAUy8MJNAa-OID7jskcRD7C5jsfClNxgqN9sS6iZOhWNL8RZGoalDzToqdea-7QRuf4BBAKe7sUrvAkSlqP4EqgTkJBOUsTMABoRuRGFUj_2IyUIJBRJ2DQ57q6gwrF57lcqwVzAMd5MNkIvc3b4P2TdMYnwjAzF1kPC4WGfU_tdRQ==" rel="nofollow" target="_blank">X</a> and <a href="https://www.globenewswire.com/Tracker?data=sU6SMdM_N775EU3h8q6E4HqPTpP_ENqezg7wc6qlU-RMfDp1jCpSe_KC_NwZ6gT6yuCjgn4ZtJiPbdUm7JY0uQdhWfJkua-NtTgxI2oBU2ZOiO09NZUjllIet6C15ErDDty90PKtOiMQbXukkX2vScrp0MD5XGT4qErUTd8lZH1a03xXwncTKMDpNXn7iKEtVrSQTohZlDIjgagzFg9JPLsmj9LVc9TE4e9RzMztg9zBxynhi-zBMiRu-CgaupF6" rel="nofollow" target="_blank">Facebook</a>. Contact: Meichiel Jennifer Weiss Sr. Director of Investor Relations and Corporate Development ir@biomeafusion.com <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcxMzg2OSM3NTg1NjUxIzIyMDg1NzI="></img> <img alt="" src="https://ml.globenewswire.com/media/ZWM5NmU5YzEtMmFlOC00ZTAwLWJkYzItMjM5MDZiMjUyNjhlLTEyMjAxMjUtMjAyNi0wNS0wNS1lbg==/tiny/Biomea-Fusion-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/d2f051eb-da8d-4233-9093-8ff1579d035f"><img src="https://ml.globenewswire.com/media/d2f051eb-da8d-4233-9093-8ff1579d035f/small/biomea-fusion-logo-rgb-rev2-email-png.png" border="0" width="150" height="40" alt="Primary Logo"></img></a>

Biomea Fusion is set to showcase critical data on icovamenib at the upcoming ADA 2026 conference, focusing on its efficacy in improving beta cell function in diabetes. This key presentation on June 7 could significantly bolster investor confidence and impact Biomea's stock performance positively.

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News